Accessibility Menu
Evommune logo

Evommune(NYSE) EVMN

Market Cap$409.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)-44%
5 YearN/A
1 YearN/A
1 Month-54%
$11.43
+0.62%
+0.07Today
Evommune last closing stock price
MetricPriceDate
Last closeUSD 11.472026-07-27
Evommune stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.52%USD 11.532026-07-20
1 month-54.45%USD 25.182026-06-26
3 month-55.16%USD 25.582026-04-28
Year to date-33%USD 17.122025-12-31
Since inception-43.85%USD 20.232025-11-06

Evommune Financials at a Glance

Market Cap

$409.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$10.00M

Net Income (TTM)

-$75.99M

EPS (TTM)

-$2.39

P/E Ratio

-4.76

Dividend

$0.00

Beta (Volatility)

0.88 (Low)

Price

$11.43

Volume

316,457

Open

$11.45

Previous Close

$11.47

Daily Range

$11.21 - $12.01

52-Week Range

$10.47 - $33.20

Estimated Earnings Date

Aug 6, 2026

EVMN News

biotech pharma researchers talk lab

1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade

James HalleyMar 10, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Evommune

Evommune creates new treatments for chronic skin and body swelling. These medicines aim to stop painful itching and redness. They help patients when standard drugs do not work well.

What is the Core Focus?

  • EVO756: Oral medicine targeting a specific protein to block itching and swelling; currently in mid-stage clinical testing for chronic hives and severe eczema.
  • EVO301: Long-acting injectable protein designed to stop inflammation; currently in mid-stage clinical testing for severe eczema and chronic bowel disease.
  • Discovery Research: Early-stage programs focusing on new ways to treat different types of chronic inflammation throughout the body.

Key Moves for Growth

  • Acquired global rights to develop and sell EVO301 from AprilBio Co. Ltd. in June 2024.
  • Launched its common stock on the New York Stock Exchange in November 2025.
  • Initiated mid-stage clinical trials for its lead drug, EVO756, in April 2025 and August 2025.
  • Reported positive early test results for EVO301 in patients with severe eczema in February 2026.

A New Way to Stop Itch

Evommune uses a dual-action approach that targets both immune cells and nerve endings to stop itching quickly. This method aims to treat the underlying cause of the disease while providing faster relief than many existing therapies.

Checking the Financial Facts

  • Revenue was $0 in Q4 2025, as the company has no products approved for sale yet.
  • Net income reached -$28.3 million in Q4 2025, worsening by 54.3% year-over-year.
  • Operating income fell to -$29.7 million in Q4 2025, a 56.5% decline from the previous year.
  • Free cash flow hit -$16.8 million in Q4 2025, improving by 24.9% from Q4 2024.

The Final Word

Evommune has moved from early research to testing its primary drug candidates in human patients. Its future depends on the results of ongoing clinical trials and potential regulatory approvals for its inflammation-focused pipeline.

AI Generated • May 3, 2026

Industry

Biotechnology

Sector

Health Care

Employees

48

CEO

Luis C. Peña

Website

www.evommune.com

Headquarters

Palo Alto, CA 94304, US

EVMN Financials

Key Financial Metrics (TTM)

Gross Margin

92.76%

Operating Margin

-899.92%

Net Income Margin

-759.87%

Return on Equity

-195.15%

Return on Capital

-39.05%

Return on Assets

-23.57%

Earnings Yield

-21.01%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$409.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

36.02M

Volume

316.46K

Avg. Volume

773.67K

Financials (TTM)

Gross Profit

$9.28M

Operating Income

-$89.99M

EBITDA

-$74.62M

Operating Cash Flow

-$80.05M

Capital Expenditure

-$318.00K

Free Cash Flow

-$80.36M

Cash & ST Invst.

$211.46M

Total Debt

$9.11M

Evommune Performance Analysis

Evommune annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-12-31USD 5,000,000N/A
20242024-12-31USD 7,000,00040.0%
20252025-12-31USD 13,000,00085.7%
Evommune sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-100.0%
Q32025-09-30N/A
Q42025-12-31-100.0%
Q12026-03-31N/A
Evommune annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-12-31USD -1.13N/A
20242024-12-31USD -2.27100.6%
20252025-12-31USD -2.18-3.8%
Evommune sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-306.2%
Q32025-09-3011.1%
Q42025-12-31-125.0%
Q12026-03-3128.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$349.00K

-113.3%

Gross Margin

0.00%

N/A

Market Cap

$409.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$8.52M

N/A

Employees

48

N/A

Net Income

-$21.67M

-48.9%

EBITDA

-$21.33M

-50.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$211.46M

+336.8%

Total Debt

$9.11M

-95.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$7.30M

-96.2%

Short Term Debt

$1.82M

+143.9%

Return on Assets

-23.57%

N/A

Return on Invested Capital

-28.86%

N/A

Free Cash Flow

-$27.59M

-15.4%

Operating Cash Flow

-$27.50M

-15.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ARTVArtiva Biotherapeutics, Inc.
$10.32+2.89%
OABIOmniAb, Inc.
$2.03+0.00%
KPTIKaryopharm Therapeutics Inc.
$7.09-4.32%
CDXSCodexis, Inc.
$1.55+4.73%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.67-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About EVMN

What is the current price of Evommune?

Evommune is trading at $11.47 per share.

What is the 52-week range for Evommune?

Over the past 52 weeks, Evommune has traded between $10.47 and $33.20.

How much debt does Evommune have?

As of the most recent reporting period, Evommune reported total debt of $9.11M.

How much cash does Evommune have on hand?

Evommune reported $48.32M in cash and cash equivalents in its most recent financial results.

What is Evommune’s dividend yield?

Evommune does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services